Examining Axatilimab in the AGAVE-201 Trial For cGVHD

Author(s):

Sergio A. Giralt, MD, discusses how the mechanism of action of axatilimab, recently approved by the FDA for chronic graft-vs-host disease (cGVHD), involves targeting CSF1R to disrupt macrophage differentiation and reduce inflammation, and how the AGAVE-201 trial demonstrated strong efficacy and safety, which will influence clinical decision-making and potentially change the GVHD treatment landscape by offering a novel therapeutic option.

EP: 1.The Pathophysiology of Chronic Graft-Vs -Host Disease (cGVHD) and the Role of CSF1R

Now Viewing

EP: 2.Examining Axatilimab in the AGAVE-201 Trial For cGVHD

EP: 3.Exploring Combination Therapy with Ibrutinib and Rituximab in cGVHD

EP: 4.Discussing Real-World Ruxolitinib and Corticosteroid Treatment Patterns in Patients with cGVHD

EP: 5.The Role of Posttransplant Cyclophosphamide in Patients With cGVHD

EP: 6.Main Conference Takeaways Regarding cGVHD Management

Video content above is prompted by the following:

What did this abstract elucidate about the mechanism of action of axatilimab, which was approved by the FDA this year as a treatment for chronic graft-vs-host disease (cGVHD)?
How will this abstract affect your clinical decision-making?
The AGAVE-201 trial led to the approval of axatilimab for cGVHD. Discuss the methods and study design of this trial.
What were the key efficacy and safety data seen in the AGAVE-201 trial with axatilimab?
How do these results influence your clinical practice?
How do you see the GVHD treatment landscape changing with the introduction of axatilimab?

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!